MUSTANG BIO, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MUSTANG BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-12-31 was $0.00.
- MUSTANG BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- MUSTANG BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- MUSTANG BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-03-31 was $48.00K.
- MUSTANG BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $48.00K, a 73.03% decline from fiscal 2023.
- MUSTANG BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $178.00K, a 13.59% decline from fiscal 2022.
- MUSTANG BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $206.00K, a 33.33% decline from fiscal 2021.
- MUSTANG BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2021 was $309.00K, a 11.46% decline from fiscal 2020.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $48.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $48.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $138.00K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $48.00K 10-Q · filed 2025-05-14 | $226.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $178.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $90.00K 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $88.00K 10-Q · filed 2024-08-13 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $206.00K 10-K · filed 2024-03-11 |
| 2022-09-30 | $90.00K 10-Q · filed 2023-11-14 | $206.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $267.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $116.00K 10-Q · filed 2023-05-12 | $267.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $309.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $151.00K 10-Q · filed 2022-11-14 | $309.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $338.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $158.00K 10-Q · filed 2022-05-12 | $35.26M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $349.00K 10-K · filed 2022-03-23 |
| 2020-09-30 | $180.00K 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $34.92M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $169.00K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |